近日,阿斯利康宣布其免疫治疗药物IMFINZI®(度伐利尤单抗)获得美国食品药品监督管理局(FDA)批准,用于治疗局限期小细胞肺癌(LS-SCLC)患者。欧洲委员会的批准是在人用药品委员会给出积极意见之后作出的,其依据是发表在《新英格兰医学杂志》上的 ADRIATIC 三期试验的结果。ADRIATIC III期试验是一项全球性、随机、双盲、安慰剂对照的研究,旨在评估IMFINZI®在局限期小细胞...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.